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erioperative Management of Patients With
rug-Eluting Stents
li O. Abualsaud, MD,* Mark J. Eisenberg, MD, MPH†
ontreal, Quebec, Canada
hrombosis of a drug-eluting stent (DES) is a catastrophic complication. The risk of stent thrombosis (ST) is
ncreased in the perioperative setting and is strongly associated with the cessation of antiplatelet therapy.
his article reviews the perioperative management of patients with DES with a clinical focus on the periop-
rative use of antiplatelet therapy. Cessation of dual antiplatelet therapy is the single most signiﬁcant pre-
ictor of perioperative ST. Available data on perioperative management of patients with DES are limited,
nd recommendations are therefore limited. To avoid ST with DES, aspirin and thienopyridines should ide-
lly be continued throughout surgery. In spite of the increased risk of bleeding, this strategy is acceptable
n many types of invasive surgical procedures with no change in outcome. However, if the bleeding risk
utweighs the risk of ST, other potential strategies include treatment with aspirin alone, “bridging therapy”
ith aspirin and a glycoprotein IIb/IIIa inhibitor and/or heparin, and “bridging therapy” without aspirin.
ovel antiplatelet therapies are promising and potentially valuable in the perioperative management of
atients with DES. Maintaining dual antiplatelet therapy is the mainstay of perioperative ST prevention.
owever, short-term discontinuation of thienopyridines might be associated with relatively low risk if aspi-
in therapy is maintained perioperatively. (J Am Coll Cardiol Intv 2010;3:131–42) © 2010 by the American
ollege of Cardiology Foundationc
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eultiple reports of perioperative stent thrombosis
ST) in patients with drug-eluting stents (DES)
ave been published. Stent thrombosis is a cata-
trophic complication, and the perioperative man-
gement of such patients is a major clinical issue.
his risk of ST is lowered primarily with the use of
ual antiplatelet therapy (1). The common practice
f cessation of dual antiplatelet therapy to avoid
xcessive perioperative bleeding should be mini-
ized, because it puts patients at a higher risk of
erioperative ST (2). American and European
uidelines recommend dual antiplatelet therapy
ith aspirin and a thienopyridine in patients with
ES for at least 12 months after percutaneous
rom the *Division of Cardiology, Royal Victoria Hospital/McGill
niversity Health Centre, Montreal, Quebec, Canada; and the †Divi-
ions of Cardiology and Clinical Epidemiology, Jewish General Hospi-
al/McGill University, Montreal, Quebec, Canada. Dr. Eisenberg is a
ational Researcher of the Quebec Foundation of Health Research.f
anuscript received August 27, 2009; revised manuscript received
ovember 17, 2009, accepted November 30, 2009.oronary intervention (PCI) to prevent ST (1–4).
his review focuses on the perioperative use of
ntiplatelet agents in patients with DES undergo-
ng noncardiac surgery and strategies to avoid ST.
ethods
earch strategy. A search was carried out in the
ubMed database with the terms: “drug eluting”,
stent thrombosis”, “perioperative”, “antiplatelet”, and
surgery”. The search captured 4,638 articles; 4,017
ere English-language articles. Of these articles, 694
ncluded DES and 414 articles involved surgeries or
erioperative settings. Ninety-nine articles remained
fter excluding unrelated articles (Fig. 1).
Our search included articles discussing pharma-
ological aspects and evidence-based uses of avail-
ble and investigational antiplatelet therapies,
articularly in a perioperative setting and their
ffect on bleeding risk. The search combined the
ollowing terms interchangeably: “perioperative”,
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132noncardiac surgery”, “non-cardiac surgery”, “antiplatelets”,
aspirin”, “thienopyridines”, “clopidogrel”, “ticlopidine”,
glycoprotein IIb/IIIa inhibitors”, “perioperative”, “bleed-
ng”, “heparin”, “prasugrel”, “AZD6140”, “drug-eluting”,
nd “late stent thrombosis”. Furthermore, due to the large
umber of references with these terms, we searched the
edical Subject Headings service provided by PubMed
ith these terms to obtain the specific results that we
ought. Finally, citations from those selected articles were
xamined for other relevant articles.
nclusion/exclusion criteria. English-language articles dis-
ussing DES, ST, and antiplatelet therapy in the peri-
perative setting were included. Non–English-language
rticles, noncoronary stents, and cardiac surgery articles
ere excluded.
ST in DES
Despite the great success of
DES, data demonstrating asso-
ciated late and very late stent
thrombosis (VLST) have raised
many concerns regarding their
safety (5–9). In response to con-
cerns of ST, a Food and Drug
Administration Circulatory Sys-
tem Advisory Panel Meeting
concluded in December 2006
that DES were associated with a
small yet significant risk of late
stent thrombosis compared with
bare-metal stents (BMS). How-
ever, the risk of death or myo-
cardial infarction was only in-
creased in off-label use, which
corresponds to at least 60% of
DES use (10). Subsequently the
American Heart Association/
merican College of Cardiology (AHA/ACC)/Society for
ardiovascular Angiography and Interventions/American
ollege of Surgeons/American Dental Association pub-
ished an advisory on the risks of premature cessation of
ntiplatelet therapy and its significance in reducing the risk
f ST and on the hazards of premature cessation (2).
Stent thrombosis is a sudden and potentially catastrophic
omplication of PCI. It usually manifests as ST-segment
levation myocardial infarction (STEMI), malignant arrhyth-
ias, or death (7,11–13). Available data demonstrate a high
ortality ranging between 9% and 45% with ST (5–9,14–18).
Stent thrombosis is a platelet-mediated process that
ccurs through progressive platelet activation and aggrega-
ion leading to thrombus formation (19,20). PCI causes
ndothelial and medial damage that heals by neointimal
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
P  glycoprotein
MWH  low molecular
eight heparin
ACE  major adverse
ardiac events
CI  percutaneous
oronary intervention
T  stent thrombosis
TEMI  ST-segment
levation myocardial
nfarction
FH  unfractionated
eparin
LST  very late stent
hrombosisormation, usually within 2 to 6 weeks with BMS (21). (owever, with DES, re-endothelialization and neointimal
ealing are delayed, keeping stent struts exposed, which
auses platelet aggregation and thrombus formation (21).
Several risk factors for ST, including stent-related,
rocedure-related, and patient-related variables, have been
escribed (Table 1) (4,8,14,16,22–28). Moreover, hyper-
ensitivity to the stent polymer has been described (29).
owever, the single most important predictor of ST is
he premature cessation of dual antiplatelet therapy
8,26,30 –34).
oncardiac Surgery and ST
he risk of perioperative ST has been well-established in
atients undergoing noncardiac surgery early after PCI. It
as demonstrated that patients undergoing noncardiac sur-
ery had increased mortality within 6 weeks after PCI
ompared with patients undergoing surgery after 6 weeks
Figure 1. Diagram Showing Our Search Strategy and Number of Articles
Included and Excluded From Our Search
DES  drug-eluting stent(s).35). After major surgery, there is a rise in thrombogenic
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133isk secondary to catecholamine release, increased platelet
ggregability, and decreased fibrinolysis leading to a hyper-
oagulable state (36–39). In addition, acute withdrawal of
ntiplatelet therapy might trigger a rebound effect and
ncrease the risk of ST (40–42). Therefore, due to such a
igh risk of mortality, prevention of thrombosis is crucial.
There are limited data concerning perioperative ST in
atients with DES (Table 2) (9,30,33,43–58). However, in
eeping with previous reports, available data suggest that
he rate of major adverse cardiac events (MACE) with DES
s higher in early surgery compared with late surgery, with
o difference between sirolimus-eluting and paclitaxel-
luting stents. Furthermore, most cases of MACE were
ssociated with the cessation of antiplatelet therapy
Table 1. Risk Factors of Stent Thrombosis in Patients With DES
Patient factors
ACS
Reduced left ventricular ejection fraction
MACE within 30 days of PCI
Diabetes mellitus
Renal insufﬁciency
Gene polymorphism
Hypercoagulable states (e.g., malignancy, surgery, diabetes)
Procedural factors
Residual dissection
Incomplete stent apposition
Stent underexpansion
“Crush” technique
Side branch occlusion
Coronary anatomy
Vessel size
Type C lesion
Left main coronary artery stent
Increased lesion length
Thrombus
Bifurcation
In-stent restenosis
Plaque characteristics
Multivessel disease
Total occlusion
Bypass graft
Stent factors
Stent surface
Hypersensitivity to polymer
Drugs
Antithrombotic and anticoagulation therapy
Cessation of antiplatelets
Antiplatelet resistance
Inhibition of platelet aggregation
Data adapted from references 4,8,14,16,22–28.
ACS acute coronary syndromes;DESdrug-eluting stent(s);MACEmajor adverse cardiac
events; PCI percutaneous coronary intervention.9,30,43,44,50–52). intiplatelet Therapy for Patients With DES
ntiplatelet agents are crucial in ST prevention, which is a
latelet-mediated process by acting on various steps of the
hrombus formation process (20). However, when used
erioperatively, antiplatelet agents are associated with an
ncreased risk of surgical bleeding. Adding thienopyridines
o aspirin (dual antiplatelet therapy) yields a synergistic
ffect and is the standard of care after DES implantation to
void ST (14). Ticlopidine is similar to clopidogrel but is
imited by side effects such as agranulocytosis and throm-
otic thrombocytopenic purpura (59,60).
In the 2007 updated ACC/AHA guidelines on manage-
ent of STEMI, the addition of thienopyridines to aspirin
s recommended regardless of reperfusion therapy for at
east 14 days and up to 1 year if there is no risk of bleeding
61). Dual antiplatelet therapy proved to be beneficial in
educing cardiac events in PCI (62–64). Furthermore, dual
ntiplatelet therapy was superior to either aspirin or thien-
pyridines alone in prevention of ST (13) and was also
uperior to the combination of aspirin and warfarin (65). In
he 2007 focused update by the ACC/AHA/Society for
ardiovascular Angiography and Interventions on PCI,
ual antiplatelet therapy is recommended for all patients
eceiving DES unless there is a high risk of bleeding (1).
he guidelines also add that in patients with clinical features
ssociated with ST (i.e., renal insufficiency, diabetes, or
rocedural characteristics, such as multiple stents or treat-
ent of a bifurcation lesion) extending dual antiplatelet
herapy beyond 1 year might be reasonable (1).
The efficacy of dual antiplatelet therapy in reducing
ACE after PCI over the first year was demonstrated by
he PCI-CURE (Clopidogrel in Unstable angina to prevent
ecurrent ischemic Events) study and the CREDO (Clo-
idogrel for the Reduction of Events During Observation)
tudy in patients undergoing PCI with BMS (62,64). In the
HARISMA (Clopidogrel for High Atherothrombotic
isk and Ischemic. Stabilization, Management and Avoid-
nce) study, a similar reduction of MACE was achieved in
econdary prevention of patients without acute coronary
yndromes and not undergoing PCI, with no significant
enefit of clopidogrel beyond 1 year, in addition to a higher
isk of bleeding (66).
erioperative bleeding with antiplatelet therapy. The single
ost important predictor of ST is the cessation of antiplate-
et therapy (8,26,30,32,67,68). Nevertheless, balancing the
isk of ST against the risk of bleeding associated with
ntiplatelet agents is critical. The effect of dual antiplatelet
herapy in surgical bleeding has been mostly studied in
ardiac surgery. Most data suggest that, at a low dose, taking
spirin perioperatively in bypass surgery is associated with a
ow risk of excessive bleeding (69–71). However, the
ddition of thienopyridines to aspirin results in a significant
ncrease in bleeding, blood product transfusions, ventilation
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134equirements, length of hospital stay, and surgical re-
xploration in patients kept on thienopyridines (72–76). In
he CURE trial, it was concluded that there was a 1%
ncrease of excessive bleeding in patients with clopidogrel
eld 5 days before coronary artery bypass graft surgery
77). For this reason, the ACC/AHA guidelines recom-
end that, in patients taking clopidogrel for whom
oronary artery bypass graft surgery is planned, the drug
hould be withheld for at least 5 days unless the urgency
or revascularization outweighs the risks of excess bleed-
ng (61).
In noncardiac surgery, the data concerning the risk of
urgical bleeding with dual antiplatelet therapy are limited
nd conflicting. In a meta-analysis by Burger et al. (40),
ncluding a total of 49,590 patients undergoing noncardiac
Table 2. Studies and Reports of MACE in Patients With DES Undergoing N
First Author (Ref. #) Patients, n Time After PCI Stent Type
Rabbitts et al. (53) 520 203.5 days median SES and PES
Schouten et al. (50) 192 0–24 months SES, PES, and BMS
Rhee et al. (54) 141 (136 NCS) 7.6 3.3 months SES and PES
Kim et al. (55) 138 Not reported DES and BMS
Brotman et al. (51) 114 125–354 days PES, SES, and BMS
Godet et al. (56) 96 1 week to 36
months
SES, PES, and BMS
Assali et al. (57) 78 183–1,125 days SES, PES and ZES
Compton et al. (58) 38 260 days median SES and PES
McFadden et al. (9) 4 331–442 days 2 SES 2 PES
Nasser et al. (44) 2 4 and 21 months SES
Head et al. (43) 2 8 and 6 months
Auer et al. (30) 1 12 weeks PES and BMS
Murphy et al. (33) 1 2 weeks SES
de Souza et al. (52) 1 29 months PES
BMS bare-metal stent(s); MACEmajor adverse cardiac events; MImyocardial infarction; PES
eluting stent(s).urgery, it was concluded that aspirin continuation led to an tncrease in bleeding by a factor of 1.5. However, this
ncrease did not lead to a higher level of the severity of
leeding complications or fatal bleeding except in intra-
ranial surgery and possibly transurethral prostatectomy.
oreover, withdrawal of aspirin was associated with a
igher incidence of cardiac, cerebral, and peripheral
ascular events (40). In a study by Payne et al. (78), a
.4-fold increase in bleeding time was observed after
ombining 75-mg clopidogrel and 150-mg aspirin in
ealthy volunteers. Therefore, it would be expected that
ual antiplatelet therapy would increase surgical bleeding.
Several case reports describe significant and even fatal
ost-operative hemorrhage with dual antiplatelet therapy
fter vascular, orthopedic, and even endoscopic procedures
79–81). However, several studies demonstrate that, even
diac Surgery
pe of Surgery Antiplatelet Therapy Outcome
rious Discontinued in 64.2% MACE in 28 patients (5.4%),
ST in 4 patients
rious Early surgery (n  30)
Discontinued in 43.3%
Late surgery (n  162)
Discontinued in 47.8%
Early surgery (n  30)
(MACE in 4 patients)
Late surgery (n  162)
(MACE in 1 patient)
All events were off antiplatelets
rious Discontinued in all ST in 7 cases (5%),
mortality in 5 cases (71%)
t reported Discontinued in all MACE in 3 pt (2.2%) on days 6,
264, and 367
rious Discontinued in 77.2% MI in 2 patients
No ST
No mortality
scular, urology,
orthopedic,
abdominal
Aspirin discontinued in 24%,
clopidogrel discontinued
in 36%
MI in 12 patients (12.5%),
ST in 1 BMS, ST in 1 DES
rious Aspirin discontinued in 82%,
clopidogrel discontinued
in 58%
MACE in 6 patients (7.7%),
mortality in 2 patients (33.3%)
rious Major surgery (aspirin
continued in 78% and
clopidogrel in 41%)
Minor surgery (aspirin
continued in 94% and
clopidogrel in 39%)
No MACE
dder
lon
doscopy
Discontinued in all ST in 4 patients, no mortality
ck Discontinued in all ST in 2 patients,
mortality in 1 patient
nsplant Discontinued in 1 patient
Held in 1 patient 1 day
pre-operative, resumed
1 day post-operative
ST in 1 patient,
bleeding in 2 patients,
no mortality
ee Discontinued ST of DES with patent BMS
dominal Held for 1 day ST, no mortality
logy Discontinued ST, no mortality
itaxel-eluting stent(s); SES sirolimus-eluting stent(s); ST stent thrombosis; ZES zotarolimus-oncar
Ty
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135ransfusion requirements, there was no change in mortality
r surgical outcome (46–48,82). Therefore, the increased
isk of perioperative hemorrhage with antiplatelet agents is
ot necessarily associated with increased morbidity, mor-
ality, or surgical outcome. Furthermore, the cessation of
ntiplatelet therapy in the setting of DES increases the
erioperative risk of ST and MACE. Therefore, the risk
f withdrawing antiplatelet therapy in patients with DES
ight outweigh the risk of retaining them particularly in
igh-risk patients. Moreover, the routine cessation of
Table 3. Hemorrhagic Risk in Noncardiac Surgery
Surgical
Hemorrhagic
Risk
Blood Transfusion
Requirement Type of Surgery
Low Usually not required Peripheral, plastic, and general surgery,
biopsies; minor orthopedic,
otolaryngology, and general surgery;
endoscopy; eye anterior chamber;
dental extraction and surgery
Intermediate Frequently required Visceral surgery; cardiovascular surgery;
major orthopedic, otolaryngology,
urologic reconstructive surgery
High Possible bleeding in
a closed space
Intracranial neurosurgery; spinal canal
surgery; eye posterior chamber
surgery
Data adapted from Chassot et al. (83).
Figure 2. Algorithm of Perioperative Management of Patients With DES
COX  cyclooxygenase; DES  drug-eluting stent(s); LMWH  low molecular
coronary intervention; ST  stent thrombosis; UFH  unfractionated heparin.ntiplatelets perioperatively should not be practiced, and
ach patient must be managed on a case-by-case basis.
trategies for Perioperative Management of DES
ecause of the lack of prospective studies and guidelines,
here are a wide variety of potential approaches to the
erioperative management of DES and antiplatelet therapy
19,43,83–91). The perioperative management of patients
ith DES should be carried out on an individual case-by-
ase basis. The approach should be managed in a multidis-
iplinary manner by the patient’s cardiologist, surgeon,
ematologist, and anesthetist. Many factors should be
onsidered, particularly the surgical hemorrhagic risk (Table 3)
nd the thrombotic risk of the DES (Table 1). Subse-
uently, the estimated risk of ST should be weighed against
he risk of bleeding (Fig. 2).
spirin and thienopyridines throughout surgery. As a gen-
ral approach, all elective surgical procedures should be
elayed by at least 6 months and ideally 12 months after
ES placement. However, if surgery cannot be delayed due
o urgency, maintaining dual antiplatelet therapy with
spirin and thienopyridines is of paramount importance as
he risk of ST is significantly increased. This applies to most
urgical procedures, except those in areas where bleeding is in
closed space and might be catastrophic, such as intracranial,
t heparin; NSAID  nonsteroidal anti-inﬂammatory drug; PCI  percutaneousweigh
s
(
r
l
P
M
g
i
c
s
a
a
r
s
r
w
t
a
D
o
t
r
a
o
r
(
t
p
u
r
a
m
(
o
“
c
b
a
H
a
a
(
o
b
s
a
s
a
e
m
a
“
I
a
a
p
i
b
(
n
o
t
p
p
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 2 , 2 0 1 0
F E B R U A R Y 2 0 1 0 : 1 3 1 – 4 2
Abualsaud and Eisenberg
Perioperative Management of Patients With DES
136pinal medullary, and posterior chamber ophthalmic surgeries
40,82). Bleeding risk is also increased in transurethral prostate
esection; however, the use of potassium-titanyl-phosphate
aser is considered safe (92,93).
Patients undergoing surgical procedures 12 months after
CI are likely at a lower risk of perioperative ST and
ACE compared with earlier surgery (2,5,64). However,
iven the increasing reports of VLST and significant delays
n re-endothelialization with DES, the risk is still signifi-
ant. Therefore, maintaining dual antiplatelet therapy
hould be a priority if the risk of perioperative bleeding is
cceptable. In contrast, if concomitant risk factors are absent
nd the hemorrhagic risk is significant, withdrawing thienopy-
idines while maintaining aspirin would be reasonable (18).
The Scottish Intercollegiate Guidelines Network (SIGN)
tate that, if emergency or urgent noncardiac surgery is
equired, dual antiplatelet therapy should be continued
henever possible unless bleeding risk is unacceptable. In
his case, antiplatelet therapy should be reintroduced as soon
s possible post-operatively (91).
iscontinue thienopyridines and maintain aspirin. If the risk
f perioperative bleeding is significantly high, whether due
o surgical factors or patient-related factors, then thienopy-
idines may be discontinued 5 days before surgery, and
spirin should be maintained. However, because ST usually
ccurs quite soon post-operatively, clopidogrel should be
estarted once the risk of bleeding has been diminished
ideally within the first 24 h) with a loading dose of 300 mg
o 600 mg (30,32,33,94).
Maintaining single antiplatelet therapy with aspirin ap-
lies to patients without concomitant risk factors of ST
ndergoing surgery more than 12 months after PCI. In a
ecent study, it was concluded that short-term discontinu-
tion of antiplatelet therapy is relatively safe if aspirin is
aintained; however, the risk of ST was still present (Fig. 3)
18). Therefore, in the case of early surgery or the presence
f ST risk factors, “bridging therapy” might be advisable.
Bridging therapy” with aspirin and heparin. Heparin is
ommonly used as a substitute to aspirin or thienopyridines,
ecause of its efficacy in the treatment of unstable angina
nd non–ST-segment elevation myocardial infarction.
owever, heparin is an antithrombin agent and not an
ntiplatelet. The use of antithrombotics such as unfraction-
ted heparin (UFH) and low molecular weight heparin
LMWH) has been proposed in perioperative management
f DES. However, these therapies have not been proven to
e effective (87). Moreover, perioperative heparin use was
till associated with high mortality (46). In addition, heparin
nd warfarin were not effective in preventing acute and
ubacute ST in the early days of BMS (95). The hyperco-
gulability after abrupt cessation of UFH has to be consid-
red as well (96). Furthermore, given that ST is a platelet-
ediated process, it is expected that antithrombotics (UFHnd LMWH) are not ideal for “bridging”. MBridging therapy” with aspirin and a glycoprotein (GP)
Ib/IIIa inhibitor. GP IIb/IIIa is a platelet integrin. Platelet
ctivation transforms the integrin into a state of high-
ffinity to fibrinogen, which is the final common pathway of
latelet aggregation and clot formation. GP IIb/IIIa inhib-
tors act by blocking fibrinogen-mediated cross-linking
etween platelets, thereby inhibiting platelet aggregation
97). Abciximab (ReoPro, Eli Lilly and Company, India-
apolis, Indiana) causes a prolonged irreversible antagonism
f GP IIb/IIIa leading to platelet aggregation inhibition
hat lasts for at least 48 h and up to 7 days (98). Given its
rolonged inhibition time, abciximab should not be used
erioperatively. The synthetic peptides eptifibatide (Integrilin,
Figure 3. Cumulative Proportion of Late Stent Thrombosis Cases Among
Patients Who Discontinued Antiplatelet Therapy
(A) Within 1 year of discontinuing antiplatelet therapy. (B) Within 30 days
of discontinuing antiplatelet therapy. Data adapted from Eisenberg et al. (18).
ASA  acetylsalicylic acid.illennium Pharmaceuticals, Boston, Massachusetts) and ti-
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137ofiban (Aggrastat, Merck and Co., Inc., West Point, Penn-
ylvania) are competitive reversible binders to GP IIb/IIIa
eceptors and dissociate rapidly with less affinity than abcix-
mab (99). Their half-life is quite short, and platelet function is
ompletely restored 2 to 4 h after stopping the infusion,
aking them potentially suitable for perioperative use.
Although GP IIb/IIIa inhibitors have not been studied in
he perioperative setting, their use as a “bridge” when
hienopyridines are stopped before surgery could be consid-
red. Ideally, “bridging” should be started within 2 to 4 days
fter stopping oral antiplatelets. This means patients would
ave to be admitted to hospital several days before surgery.
ven though this strategy is not practical in most cases, it
ight be worthwhile in patients at extremely high risk of
ES thrombosis. Moreover, if a patient is already admitted
o undergo urgent surgery, this strategy might be consid-
red. Therefore, in patients with DES with an increased risk
f perioperative bleeding and a significant risk of ST who
re undergoing surgery, bridging therapy with aspirin and a
P IIb/IIIa inhibitor with or without heparin could be
onsidered. This strategy entails stopping thienopyridines 5
ays before surgery and admitting the patient to the hospital
everal days before surgery to begin tirofiban or eptifibatide
nd UFH infusions. Both are then stopped 6 h before
urgery (87). Importantly, the bleeding risk with GP
Ib/IIIa inhibitors also has to be considered. This strategy is
ostly of theoretical interest at the present time. We know
f no large studies examining this strategy. The only study
e could find was a recent report of 7 patients considered to
e at a high risk of both ST and surgical bleeding. In these
atients, it was demonstrated that bridging with eptifibatide
as associated with a good post-operative outcome without
ncreased perioperative hemorrhage (100).
iscontinue both aspirin and thienopyridines and consider
ther alternatives. If the risk of surgical bleeding is poten-
ially catastrophic or fatal, such as in intracranial, medullary,
nd posterior chamber surgeries, aspirin cessation might be
ecessary. In these cases aspirin and thienopyridines should
e discontinued 5 days before surgery. Given the increased
isk of ST with cessation of antiplatelet agents, intensive
erioperative monitoring and early interventions are of
aramount importance. Moreover, dual antiplatelet therapy
hould be reintroduced once the risk of hemorrhage is
iminished.
In patients with concomitant risk factors of ST, “bridging
herapy” with a GP IIb/IIIa inhibitor with or without
eparin could be considered. According to recommenda-
ions of the French Society of Anesthesiology and Intensive
are, if withdrawal of antiplatelet agents is necessary,
ubstitution of another nonsteroidal anti-inflammatory drug
uch as flurbiprofen (50 mg  2, withdrawn 24 h before
urgery) or LMWH (85 to 100 IU aXa/kg for 12 h) might
e indicated (90). rThe use of nonselective cyclooxygenase-1 inhibitor non-
teroidal anti-inflammatory drugs as an alternative to aspirin
uch as flurbiprofen, sulfinpyrazone, indobufen, or triflusal
as been studied. The main advantage is their reversible
ntiplatelet effect and that platelet function is restored
ithin 24 h after discontinuation. However, randomized
linical trials revealed conflicting results (101). Even though
t is unknown how well they perform in the perioperative
etting, their use as an alternative in high-risk surgery could
e considered.
Patients undergoing surgical procedures after 12 months
f PCI have a lower risk of perioperative ST and MACE
ompared with earlier surgery (35). However, given the
ncreasing reports of VLST and significant delay in re-
ndothelialization with DES, the risk is still significant.
herefore, maintaining dual antiplatelet therapy should be
f paramount importance if the risk of perioperative bleed-
ng is acceptable. In contrast, if concomitant risk factors are
bsent and the hemorrhagic risk is significant, withdrawing
hienopyridines while maintaining aspirin would be reason-
ble. However, in patients with risk factors of ST undergo-
ng procedures with a significant hemorrhagic risk, “bridg-
ng” therapy could be considered.
anagement of Perioperative Hemorrhage
atients undergoing any type of surgery should have a
latelet count of at least 50,000/l to minimize the risk of
emorrhage (68,102). This hemorrhagic risk threshold is
ncreased to 100,000/l in patients undergoing neurosur-
ery or posterior chamber ophthalmic surgery (103). He-
ostasis requires the presence of at least 50% of functional
latelets. Because the effect of antiplatelet agents is not
eversible, fresh platelets are the only way to re-establish
ormal coagulation. However, new platelets might be affected
y residual drug in the circulation. Clopidogrel has a half-life of
h (104). Thus, in the case of major bleeding, hemostasis
ight be restored with fresh platelet concentrate transfusion
fter 16 to 24 h from the last intake without significant
nhibition. The plasma half-life of tirofiban and eptifibatide is
lose to 2 h, and 60% to 90% of normal platelet function is
estored after 6 h from discontinuation (99). Fresh platelet
ransfusion is rarely required in this case.
Transfusion of 1 platelet concentrate usually increases
erum platelet count by 5,000/l to 10,000/l 1 h after
ransfusion in a 70-kg adult (105). However, several risk
actors play a role in the response to platelet transfusions
106). Other supportive measures include the replacement
f lost blood by the transfusion of packed red cells or other
lood products such as cryoprecipitate, fresh frozen plasma,
ecombinant factor VII, and desmopressin.
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138anagement of Post-Operative ST
ecause ST most often presents as an STEMI, the most
ppropriate management is early reperfusion therapy. Post-
perative thrombolytic therapy is not possible, given the
xcessive risk of bleeding. Moreover, thrombolytic therapy
s less effective when compared with primary PCI and might
e even less effective in cases of ST, which is more
latelet-mediated (107). Therefore, primary PCI is the
reatment of choice for perioperative ST. Patients carrying a
igher risk of ST, whether due to the cessation of dual
ntiplatelet therapy or the presence of concomitant risk
actors, should be monitored closely post-operatively until
ual antiplatelet therapy is fully restarted.
ovel Antiplatelets
arious novel antiplatelet agents are expected to be released
n the near future. Available data demonstrate results that
ould most likely facilitate the perioperative management
f DES and likely will change our current approach.
Prasugrel is a novel orally administered thienopyridine
rodrug metabolized via cytochrome P450 in the liver.
rasugrel has been recently approved by the Food and Drug
dministration for use with PCI (108). Similar to clopi-
ogrel, prasugrel binds selectively and irreversibly to the
latelet P2Y12 receptor (109). However, prasugrel has a
uch more rapid, potent, and consistent platelet inhibition,
ith a loading dose of 60 mg compared with the standard
00 mg of clopidogrel (110,111). The TRITON–TIMI 38
TRial to Assess Improvement in Therapeutic Outcomes by
ptimizing Platelet InhibitioN with Prasugrel–Thrombolysis
n Myocardial Infarction 38) clinical trial compared clopi-
ogrel use of 300-mg loading dose and 75-mg daily dose
ith prasugrel with a 60-mg loading dose and 10-mg daily
ose in acute coronary syndromes (112). A significant
eduction of ischemic events was demonstrated. The inci-
ence of ST was decreased from 2.4% with clopidogrel to
.1% with prasugrel. However, there was an increased risk
f bleeding, including fatal bleeding. In The PRINCIPLE–
IMI 44 (Prasugrel in Comparison to Clopidogrel for
nhibition of Platelet Activation and Aggregation–
hrombolysis In Myocardial Infarction 44) trial, the use of
rasugrel loading dose of 60 mg and maintenance daily dose
f 10 mg achieved a greater level of platelet function
nhibition compared with high-dose clopidogrel with
00-mg loading dose and 150-mg maintenance daily dose
mongst patients undergoing PCI (113). However, fre-
uency of bleeding tended to be more with prasugrel. Even
hough prasugrel seems to be effective in patients with acute
oronary syndromes undergoing PCI, its perioperative use
ight be limited, given the increased risk of bleeding and itsrreversible antiplatelet inhibition. Prasugrel would poten- iially be useful immediately after surgery due to rapid and
otent platelet inhibition.
Ticagrelor (AZD6140) is also a novel oral adenosine
iphosphate P2Y12 receptor antagonist. Unlike clopidogrel,
iclopidine, and prasugrel, ticagrelor is a nonthienopyridine
denosine triphosphate analog that binds directly and re-
ersibly to P2Y12 without any metabolic activation. It was
emonstrated that ticagrelor achieved a greater platelet
ggregation inhibition compared with clopidogrel (114).
urthermore, peak inhibition was observed 2 to 4 h after a
ose of ticagrelor. This was demonstrated as well in the
hase 2 DISPERSE-2 (Dose confirmation Study assessing
nti-Platelet Effects of AZD6140 vs. clopidogRel in non–
T-segment Elevation myocardial infarction) trial, showing
reater mean levels of platelet inhibition than clopidogrel
ith no significant risk of bleeding (115,116). The recent
hase 3 clinical PLATO (PLATelet inhibition and patient
utcomes) trial demonstrated a significant reduction in
ACE with ticagrelor compared with clopidogrel (117).
oreover, ST was reduced to 2.9% with ticagrelor com-
ared with 3.8% with clopidogrel. Furthermore, there was
o significant difference in the rates of major bleeding. The
ain advantage of using ticagrelor perioperatively would be
ts reversibility, relatively short half-life (6 to 13 h), and its
apid onset of action (109). Patients with DES would
iscontinue ticagrelor only 1 day before surgery and it would
e resumed soon after surgery, thus diminishing both the
isk of perioperative hemorrhage and ST.
Cangrelor is also a novel reversible P2Y12 receptor antag-
nist that is administered intravenously. Similar to ticagre-
or, cangrelor does not require metabolic activation. Phase 2
tudies demonstrate a rapid onset of action and a greater
egree of platelet inhibition compared with clopidogrel.
urthermore, when compared with abciximab, incidence of
dverse cardiac events was similar in both, and platelet
ggregation returned to baseline more rapidly after stopping
he infusion with cangrelor (109,118). The phase 3
HAMPION (Cangrelor Versus Standard Therapy to
chieve Optimal Management of Platelet Inhibition) clin-
cal trial has been discontinued due to failure to meet
fficacy endpoints. However, the BRIDGE (Maintenance of
latelet inhiBition With cangRelor After dIscontinuation of
hienopyriDines in Patients Undergoing surGEry) trial is
ngoing to show safety in “bridging” patients perioperatively
119). Given its rapid onset, reversibility, and a 3-min half-life,
angrelor would be a potential “bridging therapy” in the
erioperative setting. However, similar to bridging with GP
Ib/IIIa inhibitors, patients would require prior admission for
nitiation of intravenous infusion. In this case, cangrelor would
e stopped minutes before procedure and resumed sooner than
ther antiplatelets post-operatively. Moreover, even maintain-
ng cangrelor throughout surgery might be considered, given
ts clinical profile.
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139PRT060128 (Portola, San Francisco, California) is an
nvestigational, direct-acting, reversible P2Y12 receptor an-
agonist that can be administered orally or intravenously
109). Various other novel antiplatelet agents, such as the
rotease-activated receptor-1 antagonist E5555, thrombin
eceptor antagonists such as SCH-530348, and new throm-
oxane inhibitors such as the NCX-4016 are all undergoing
nvestigations (109). Therefore, perioperative management
f patients with DES is likely to evolve with the release of
ewer antiplatelet agents.
onclusions
erioperative management of patients with DES is a critical
ssue. Maintenance of dual antiplatelet therapy remains the
ainstay of ST prevention. In cases with high risk for
leeding, maintaining short-term single antiplatelet therapy
ith aspirin is associated with low risk of ST. If aspirin must
e discontinued, various management strategies could be
onsidered, although there are few evidence-based data in
his regard. Furthermore, intensive post-operative monitor-
ng and prompt intervention are of paramount importance
hould ST occur. With additional prospective trials and
egistry formation, further information could be obtained to
id in the release of official guidelines. Moreover, the release
f novel reversible antiplatelet agents would likely change
urrent strategies, making perioperative management of
atients with DES a less-complicated task.
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